AI & ChatGPT searches , social queriess for BUROSUMAB
Search references for BUROSUMAB. Phrases containing BUROSUMAB
See searches and references containing BUROSUMAB!
Search references for BUROSUMAB. Phrases containing BUROSUMAB
See searches and references containing BUROSUMAB!BUROSUMAB
Monoclonal antibody designed to treat X-linked hypophosphatemia
Burosumab, sold under the brand name Crysvita, is a human monoclonal antibody medication approved 2018 for the treatment of X-linked hypophosphatemia
Burosumab
American biopharmaceutical company
Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and
Ultragenyx
Medical condition
hypophosphataemia treated with a human monoclonal antibody against FGF23 called burosumab improved significantly compared to conventional therapy. "Entry - #193100
Autosomal dominant hypophosphatemic rickets
Autosomal_dominant_hypophosphatemic_rickets
Antibodies from clones of the same blood cell
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Monoclonal_antibody
Monoclonal antibody against amyloid beta
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Lecanemab
X-linked dominant disorder that causes rickets
for this condition, called burosumab. It was then licensed by the US Food and Drug Administration in June 2018 Burosumab is shown to target the major
X-linked_hypophosphatemia
Drug class
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Anti-amyloid_antibodies
Monoclonal antibody against amyloid beta
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Donanemab
Tricyclic antidepressant
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Amitriptyline
Pharmaceutical drug
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Evolocumab
Monoclonal antibody
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Trevogrumab
Chemical compound
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Bimagrumab
Monoclonal antibody
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Emicizumab
Combination drug
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Pertuzumab/trastuzumab/hyaluronidase
Pertuzumab/trastuzumab/hyaluronidase
Peptide hormone
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Insulin
Medication for treatment of non-small-cell lung cancer
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Erlotinib
Primary male sex hormone
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Testosterone
Medication
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Idarucizumab
Chemical compound
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Lenvatinib
Sex-specific patterns of inheritance
included phosphate supplements and active vitamin D analogs. More recently, burosumab, a monoclonal antibody that targets FGF23, has been approved and shown
Sex_linkage
Experimental monoclonal antibody
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Prasinezumab
Cancer medication
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Sunitinib
Corticosteroid medication
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Dexamethasone
Chemical compound
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Dihexa
Protein-coding gene in the species Homo sapiens
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Erythropoietin_receptor
Protein found in humans
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Tropomyosin_receptor_kinase_A
Monoclonal antibody
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Abelacimab
Pharmaceutical drug
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Romosozumab
Chemical compound
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Dehydroepiandrosterone
Medication
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Bevacizumab
Antibodies from non-human species made nearly identical with human ones
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Humanized_antibody
Monoclonal antibody
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Refanezumab
Protein involved in blood vessel growth
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Vascular endothelial growth factor
Vascular_endothelial_growth_factor
Protein-coding gene in the species Homo sapiens
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
RAMP1
Pharmaceutical biological monoclonal antibody
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Fremanezumab
Monoclonal antibody
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Bedinvetmab
Protein-coding gene in the species Homo sapiens
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Ephrin_B3
Chemical compound
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Tesevatinib
Chemical compound
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Bosutinib
Experimental drug for neurodegenerative disorders
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Cerebrolysin
Medication
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Concizumab
Drugs that inhibit α-synuclein
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Anti-α-synuclein_drug
Medication
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Marstacimab
Protein-coding gene in mammals
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Fibroblast_growth_factor_21
Family of proteins involved in anatomical development
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Fibroblast_growth_factor
TrkA and TrkB positive modulator
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
ACD856
Monoclonal antibody
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Galcanezumab
Protein that stimulates red blood cell production
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Erythropoietin
Monoclonal antibody against amyloid beta
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Aducanumab
Family of proteins
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Neurotrophin
Synthetic protein
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
IGF-1_LR3
Class of compounds
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
C-Met_inhibitor
Human monoclonal antibody
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Denosumab
Chemical compound
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Imatinib
Group of signal transduction pathways involved in embryonic development
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Wnt_signaling_pathway
Protein found in humans
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Insulin-like_growth_factor_1
Chemical compound
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Tropoflavin
Mammalian protein found in humans
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
HER2
Transmembrane receptors involved in cellular adhesion and signalling
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Integrin
Class of enzymes
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Receptor_tyrosine_kinase
age-related macular degeneration Brontictuzumab mab humanized Notch 1 cancer Burosumab Crysvita mab human FGF 23 Y X-linked hypophosphatemia Cabiralizumab mab
List of therapeutic monoclonal antibodies
List_of_therapeutic_monoclonal_antibodies
Medication
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Repotrectinib
Medical condition
treatments, hence minimising its impact on the child.[citation needed] Burosumab injection Drug therapy for maintaining normal calcium and phosphate levels
Phosphate_diabetes
Medication
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Trastuzumab_deruxtecan
Protein or other substance that stimulates cellular proliferation
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Growth_factor
Chemical compound
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Caplacizumab
Chemical compound
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Dasatinib
Signaling glycoprotein regulating cell proliferation
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Platelet-derived growth factor
Platelet-derived_growth_factor
Protein found in humans
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Brain-derived neurotrophic factor
Brain-derived_neurotrophic_factor
Chemical compound
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Erenumab
Monoclonal antibody
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Eptinezumab
Targeted cancer drug
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Vemurafenib
Medication which blocks growth of blood vessels
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Anti-VEGF
Medication
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Ponatinib
Pharmaceutical drug
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Alirocumab
Mammalian protein found in humans
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Adrenomedullin
Protein-coding gene in humans
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
EPH_receptor_A2
Drug typically used in cancer treatment
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Tyrosine_kinase_inhibitor
Protein that stimulates cell division and differentiation
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Epidermal_growth_factor
Medication
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Trastuzumab
Medication
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Filgrastim
Chemical compound
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Blosozumab
Chemical compound
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Pazopanib
Medication and naturally occurring steroid hormone
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Testosterone_(medication)
Class of drugs used to treat malignant tumors
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Antineoplastic
Protein-coding gene in the species Homo sapiens
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Neuregulin_2
Chemical compound, used as a medication to treat lung cancer
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Osimertinib
Pharmaceutical compound
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Braegen-02
Pharmaceutical drug
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Cetuximab
Protein-coding gene in the species Homo sapiens
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Ephrin_A3
Protein-coding gene in the species Homo sapiens
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Ephrin_A4
Protein involved in blood vessel growth
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Vascular endothelial growth factor A
Vascular_endothelial_growth_factor_A
Protein-coding gene in the species Homo sapiens
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Kinase_insert_domain_receptor
Protein-coding gene in the species Homo sapiens
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
GFRA3
Medication for macular degeneration
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Faricimab
Mammalian protein found in humans
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Nerve_growth_factor
Monoclonal antibody protein
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Gantenerumab
Chemical compound
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
Fosgonimeton
Monoclonal antibody medication
bone, musculoskeletal, circulatory, and neurologic systems Bone Human Burosumab Denosumab Humanized Blosozumab† Romosozumab Musculoskeletal Human Stamulumab†
Solanezumab
Chemical compound
(bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23) FGFR4 Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8,
N-Acetylserotonin
BUROSUMAB
BUROSUMAB
BUROSUMAB
BUROSUMAB
Girl/Female
Indian, Sikh
Religious Song of God
Girl/Female
Irish
Bard.
Biblical
that hears; that obeys
Girl/Female
Norse
Love.
Surname or Lastname
English
English : variant spelling of Darbyshire.
Girl/Female
Tamil
Ahladita | அஹலாதிதா
In Happy mood, Delighted
Male
Danish
, spear, weapon.
Boy/Male
Muslim/Islamic
Praising Allah, commendable
Surname or Lastname
English
English : unexplained.
Girl/Female
Indian
Most beautiful woman
BUROSUMAB
BUROSUMAB
BUROSUMAB
BUROSUMAB
BUROSUMAB